Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2004

Open Access 01-12-2004 | Research article

Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells

Authors: Katherine L Meyer-Siegler, Erica C Leifheit, Pedro L Vera

Published in: BMC Cancer | Issue 1/2004

Login to get access

Abstract

Background

The importance of various inflammatory cytokines in maintaining tumor cell growth and viability is well established. Increased expression of the proinflammatory cytokine macrophage migration inhibitory factor (MIF) has previously been associated with various types of adenocarcinoma.

Methods

MIF IHC was used to localize MIF in human bladder tissue. ELISA and Western blot analysis determined the synthesis and secretion of MIF by human bladder transitional cell carcinoma cells. The effects of MIF inhibitors (high molecular weight hyaluronate (HA), anti-MIF antibody or MIF anti-sense) on cell growth and cytokine expression were analyzed.

Results

Human bladder cancer cells (HT-1376) secrete detectable amounts of MIF protein. Treatment with HA, anti-MIF antibody and MIF anti-sense reduced HT-1376 cell proliferation, MIF protein secretion, MIF gene expression and secreted inflammatory cytokines. Our evidence suggests MIF interacts with the invariant chain, CD74 and the major cell surface receptor for HA, CD44.

Conclusions

This study is the first to report MIF expression in the human bladder and these findings support a role for MIF in tumor cell proliferation. Since MIF participates in the inflammatory response and bladder cancer is associated with chronic inflammatory conditions, these new findings suggest that neutralizing bladder tumor MIF may serve as a novel therapeutic treatment for bladder carcinoma.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics. CA Cancer J Clin. 2003, 53: 5-26.CrossRefPubMed
2.
Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D, Cancer and Leukemia Group B: Overview of bladder cancer trials in the cancer and leukemia group B. Cancer. 2003, 97: 2090-2098. 10.1002/cncr.11299.CrossRefPubMed
3.
Piazza GA, Thompson WJ, Pamukeu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE, Klein-Szanto AJ, Farnell DR, Eto I, Grubbs CJ: Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001, 61: 3961-3968.PubMed
4.
Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF: Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989, 141: 22-29.PubMed
5.
La Vecchia C, Negri E, D'Avanzo B, Savoldelli R, Francesci S: Genital and urinary tract disease and bladder cancer. Cancer Res. 1991, 51: 629-631.PubMed
6.
Vera PL, Meyer-Siegler KL: Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat. BMC Neuroscience. 2003, 4: 17-10.1186/1471-2202-4-17.CrossRefPubMedPubMedCentral
7.
Vera PL, Ordorica RC, Meyer-Siegler KL: Hydrochloric acid-induced changes in macrophage migration inhibitory factor in the bladder, peripheral and central nervous system of the rat. J Urol. 2003, 170: 623-627.CrossRefPubMed
8.
Meyer-Siegler KL, Ordorica RC, Vera PL: Macrophage migration inhibitory factor is upregulated in an endotoxin-induced model of bladder inflammation in rats. J Interferon and Cytokine Res. 2004, 24: 55-63. 10.1089/107999004772719918.CrossRef
9.
Swope MD, Lolis E: Macrophage migration inhibitory factor: cytokine, hormone or enzyme?. Rev Physiol Biochem Pharmacol. 1999, 139: 1-32.PubMed
10.
Baugh JA, Bucala R: Macrophage migration inhibitory factor. Crit Care Med. 2002, 30: S27-S35. 10.1097/00003246-200201001-00004.CrossRef
11.
Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993, 365: 756-759. 10.1038/365756a0.CrossRefPubMed
12.
Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF: Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis & Rheumatism. 1999, 42: 1601-1608. 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B.CrossRef
13.
de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C, Sahli MA: Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001, 2: 1061-1066. 10.1038/ni720.CrossRefPubMed
14.
Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000, 89: 334-341. 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.3.CO;2-E.CrossRefPubMed
15.
Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res. 2002, 93: 389-396.CrossRefPubMed
16.
Meyer-Siegler K, Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 1996, 48: 448-452. 10.1016/S0090-4295(96)00207-5.CrossRefPubMed
17.
Meyer-Siegler KL, Bellino MA, Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 2002, 94: 1449-1456. 10.1002/cncr.10354.CrossRefPubMed
18.
Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S: Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci. 2003, 995: 171-182.CrossRefPubMed
19.
Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R: An essential role for macrophage migration inhibitory factor in angiogenesis and the growth of a murine lymphoma. Molecul Med. 1999, 5: 181-191.
20.
Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R: MIF Signal Transduction initiated by binding to CD74. J Exp Med. 2003, 197: 1467-1476. 10.1084/jem.20030286.CrossRefPubMedPubMedCentral
21.
Wraight C, vanEndert P, Moller P, Lipp J, Ling N, MacLennan CKN, Moldenhauer G: Human major histocompatibility class II invariant chain is expressed on the cell surface. J Biol Chem. 1990, 265: 5787-5792.PubMed
22.
Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J: The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell. 1993, 74: 257-268. 10.1016/0092-8674(93)90417-O.CrossRefPubMed
23.
Naujokas MF, Arneson LS, Fineschi B, Peterson ME, Sitterding S, Hammond AT, Reilly C, Lo D, Miller J: Potent effects of low levels of MHC class II-associated invariant chain on CD4+ T cell development. Immunity. 1995, 3: 359-372. 10.1016/1074-7613(95)90120-5.CrossRefPubMed
24.
Cichy J, Bals R, Potempa J, Mani A, Pure E: Proteinase-mediated release of epithelial cell associated CD44. J Biol Chem. 2002, 277: 44440-44447. 10.1074/jbc.M207437200.CrossRefPubMed
25.
Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ: Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathology. 2002, 160: 441-447.CrossRef
26.
van der Gaag R, Broersma L, Koornneef L: The influence of high molecular weight sodium hyaluronate (Healon) on the production of migration inhibitory factor. Curr Eye Res. 1987, 6: 1433-1440.CrossRefPubMed
27.
Meyer-Siegler K, Fattor RA, Hudson PB: Expression of macrophage migration inhibitory factor in the human prostate. Diag Mol Path. 1998, 7: 44-50. 10.1097/00019606-199802000-00008.CrossRef
28.
Seydel KB, Ellen LI, Swanson PE, Stanely SL: Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect Immun. 1997, 65: 1631-1639.PubMedPubMedCentral
29.
Lokeshwar VB, Young MJ, Goudarzi G, Iida N, Yudin AI, Cherr GN, Selzer MG: Identification of bladder tumor-derived hyaluronidase: Its similarity to HYAL1. Cancer Res. 1999, 59: 4464-4470.PubMed
30.
Meyer-Siegler K: Cox-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induced neuroendocrine differentiation in C4-2b prostate cancer cells. Molecular Medicine. 2001, 7: 850-860.PubMedPubMedCentral
31.
Mitchell RA, Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000, 10: 359-66. 10.1006/scbi.2000.0328.CrossRefPubMed
32.
Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF, Tosi P: Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis. 1997, 18: 2832-2841.CrossRefPubMed
33.
White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003, 9: 853-860.PubMed
34.
Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S: Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med. 1998, 4: 707-714.PubMedPubMedCentral
35.
Akbar SM, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, Michitaka K, Horiike N, Onji M: Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 2001, 171: 125-132. 10.1016/S0304-3835(01)00606-1.CrossRefPubMed
36.
Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST: Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003, 107: 22-29. 10.1002/ijc.11287.CrossRefPubMed
37.
Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel T: Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol. 2003, 162: 11-17.CrossRefPubMedPubMedCentral
38.
Sasaki Y, Kasuya K, Nishihira J, Magami Y, Tsuchida A, Aoki T, Koyanagi Y: Suppression of tumor growth through introduction of an antisense plasmid of macrophage migration inhibitory factor. Int J Mol Med. 2002, 10: 579-583.PubMed
39.
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999, 190: 1375-1382. 10.1084/jem.190.10.1375.CrossRefPubMedPubMedCentral
40.
Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, Iwanaga T, Nakamura H, Mizue Y, Asaka M: Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology. 2002, 123: 256-70. 10.1053/gast.2002.34236.CrossRefPubMed
41.
Lolis E, Bucala R: Macrophage migration inhibitory factor. Expert Opin Ther Targets. 2003, 7: 153-164. 10.1517/eott.7.2.153.23778.CrossRefPubMed
42.
Murakami H, Akbar SM, Matsui H, Horiike N, Onji M: Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol. 2002, 128: 504-510. 10.1046/j.1365-2249.2002.01838.x.CrossRefPubMedPubMedCentral
43.
Matza D, Kerem A, Shachar I: Invariant chain, a chain of command. Trends in Immunology. 2003, 24: 264-268. 10.1016/S1471-4906(03)00073-5.CrossRefPubMed
44.
Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994, 179: 1895-1902. 10.1084/jem.179.6.1895.CrossRefPubMed
45.
Stavitsky AB, Xianli J: In vitro and in vivo regulation by macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cellular Immunol. 2002, 217: 95-104. 10.1016/S0008-8749(02)00516-6.CrossRef
46.
Matza D, Wolstein O, Dikstein R, Shachar I: Invariant chain induces B cell maturation by activating TAFII105-NF-κβ dependent transcription program. J Biol Chem. 2001, 276: 27203-27206. 10.1074/jbc.M104684200.CrossRefPubMed
47.
48.
Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M: Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem. 2003, 278: 32259-32265. 10.1074/jbc.M300347200.CrossRefPubMed
49.
Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H: Proteolytic release of CD44 intracellular domain and its role in CD44 signaling pathway. J Cell Biol. 2001, 155: 755-762. 10.1083/jcb.200108159.CrossRefPubMedPubMedCentral
50.
Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001, 15: 968-980. 10.1101/gad.189601.CrossRefPubMedPubMedCentral
51.
Mitchell RA, Metz CN, Peng T, Bucala R: Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem. 1999, 274: 18100-18106. 10.1074/jbc.274.25.18100.CrossRefPubMed
Metadata
Title
Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells
Authors
Katherine L Meyer-Siegler
Erica C Leifheit
Pedro L Vera
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2004
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-4-34

Other articles of this Issue 1/2004

BMC Cancer 1/2004 Go to the issue

Research article

Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers

Research article

Plasma prolactin in patients with colorectal cancer

Research article

Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases – an evidence-based practice guideline

Research article

Characterization of a novel large deletion and single point mutations in the BRCA1gene in a Greek cohort of families with suspected hereditary breast cancer

Research article

G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer

Research article

Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits